Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 619 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... January 20, 2023 For Women With Dense Breasts, An MRI May Be A Better... November 29, 2019 Opinion: ‘The idea that a tobacco company might profit off my... September 1, 2021 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 Load more HOT NEWS Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to...
